首页 中华放射学杂志 2019年53卷5期 对比剂钆贝葡胺儿童中枢神经系统MRI增强检查中国专家共识
中华放射学杂志
期刊首页
过刊列表
高级检索
稿件发表
• 规范与共识 •
ENGLISH ABSTRACT
对比剂钆贝葡胺儿童中枢神经系统MRI增强检查中国专家共识
中华医学会放射学分会儿科学组 
中华医学会儿科学分会放射学组
作者及单位信息
·
DOI： 10.3760/cma.j.issn.1005-1201.2019.05.001
Chinese expert consensus on contrast agent gadobenate dimeglumine for enhanced MRI of center nervous system in children
Pediatric Group of Chinese Society of Radiology, Chinese Medical Association
Radiology Group of Chinese Society of Pediatric, Chinese Medical Association
Authors Info & Affiliations
Pediatric Group of Chinese Society of Radiology, Chinese Medical Association
Radiology Group of Chinese Society of Pediatric, Chinese Medical Association
·
DOI： 10.3760/cma.j.issn.1005-1201.2019.05.001
1572
375
0
0
20
1
扫描转手机阅读
下载中华医学期刊APP阅读更流畅 体验更丰富
PDF下载
APP内阅读
摘要
钆贝葡胺是一种非特异性细胞外间隙对比剂，具有高弛豫率和肾脏、胆道双重排泄的特点。目前对国内儿童钆贝葡胺的临床应用尚缺乏统一的认识。经中华医学会放射学分会儿科学组、中华医学会儿科学分会放射学组多名儿科影像专家反复讨论，以翔实的文献为依据，结合临床应用经验，对钆贝葡胺的理化特性、药代动力学特点、儿童中枢神经系统增强检查临床应用及安全性等达成共识。钆贝葡胺禁用于钆对比剂过敏的患者。由于钆贝葡胺能在显著缩短人体组织氢原子的纵向弛豫时间的同时缩短横向弛豫时间，因此儿童中枢神经系统增强检查应用0.10 mmol/kg剂量的钆贝葡胺可获得高质量的图像，即使应用半剂量0.05 mmol/kg在常规中枢神经系统增强中也能满足诊断需要。钆贝葡胺不良反应发生率低，严重肾功能不全的患儿仍可以安全使用。
儿童;中枢神经系统;磁共振成像;钆贝葡胺
引用本文
中华医学会放射学分会儿科学组,中华医学会儿科学分会放射学组. 对比剂钆贝葡胺儿童中枢神经系统MRI增强检查中国专家共识[J]. 中华放射学杂志,2019,53(5)：329-335.
DOI:10.3760/cma.j.issn.1005-1201.2019.05.001PERMISSIONS
Request permissions for this article from CCC.
评价本文
*以上评分为匿名评价
本文评分
0分
[累计0个]
向我们报错
版权归中华医学会所有。
未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。
除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。
钆贝葡胺（gadobenate dimeglumine，Gd- BOPTA）是一种由顺磁性钆离子和螯合剂BOPTA结合的非特异性细胞外间隙对比剂，具有高弛豫率和肾脏、胆道双重排泄的特点
[
1
,
2
,
3
,
4
]，因此广泛应用于成人中枢神经系统MRI增强检查中。目前在国内，Gd-BOPTA在儿童中枢神经系统增强检查中的应用尚仅限于少数几个大的儿童专科医疗中心，其临床应用价值未能充分发挥，且缺乏统一的认识。中华医学会放射学分会儿科学组、中华医学会儿科学分会放射学组多名儿科影像专家多次讨论，以翔实的参考文献为依据，结合临床应用经验，对Gd-BOPTA的理化特性、药代动力学特点、儿童中枢神经系统增强检查临床应用及安全性等达成了共识。共识的发布旨在规范和指导Gd-BOPTA在儿童中枢神经系统增强检查中的应用，提高儿科医师对MRI增强检查对比剂的整体认识水平，合理使用对比剂，提高检查效力，使儿童患者最大程度受益。希望国内同仁提出宝贵意见和建议，以期对本共识进一步修订和完善。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
已是订阅账户?
登录
参考文献
[1]
Cavagna FM , Maggioni F , Castelli PM ,et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging[J]. Invest Radiol, 1997,32(12):780-796.
[2]
Giesel FL , von Tengg-Kobligk H , Wilkinson ID ,et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents[J]. Invest Radiol, 2006,41(3):222-228. DOI:
10.1097/01.rli.0000192421.81037.d5
.
[3]
Brismar TB , Dahlstrom N , Edsborg N ,et al. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers[J]. Acta Radiol, 2009,50(7):709-715. DOI:
10.1080/02841850903055603
.
[4]
Spinazzi A , Lorusso V , Pirovano G ,et al. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers[J]. Acad Radiol, 1999,6(5):282-291.
[5]
Shen Y , Goerner FL , Snyder C ,et al. T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T[J]. Invest Radiol, 2015,50(5):330-338. DOI:
10.1097/RLI.0000000000000132
.
[6]
Pintaske J , Martirosian P , Graf H ,et al. Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla[J]. Invest Radiol, 2006,41(3):213-221. DOI:
10.1097/01.rli.0000197668.44926.f7
.
[7]
Rohrer M , Bauer H , Mintorovitch J ,et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths[J]. Invest Radiol, 2005,40(11):715-724.
[8]
MultiHance product label[EB/OL]. Availableat:http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021357s009lbl.pdf. (accessed November 20, 2018).
[9]
Pirovano G , Kirchin MA , Lorusso V ,et al. Pharmacokinetics of gadobenate dimeglumine in children 2 to 5 years of age undergoing MRI of the central nervous system[J]. J Magn Reson Imaging, 2015,41(4):1096-1103. DOI:
10.1002/jmri.24653
.
[10]
La Noce A , Frigeni V , Filatori I ,et al. Neurotolerability of gadobenate dimeglumine. Evaluation of brain dopamine concentration in freely moving rats by microdialysis[J]. Invest Radiol, 1999,34(8):543-547.
[11]
Brown JJ , Hynes MR , Wible JH Jr. Measurement of serum calcium concentration after administration of four gadolinium-based contrast agents to human volunteers[J]. AJR Am J Roentgenol, 2007,189(6):1539-1544. DOI:
10.2214/AJR.07.2464
.
[12]
Anzalone N , Scarabino T , Venturi C ,et al. Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting[J]. Eur J Radiol, 2013,82(1):139-145. DOI:
10.1016/j.ejrad.2011.07.005
.
[13]
Tombach B , Benner T , Reimer P ,et al. Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol[J]. Radiology, 2003,226(3):880-888. DOI:
10.1148/radiol.2263011970
.
[14]
刘哲,孙青,杨健. MR钆对比剂的儿科应用现状[J]. 中华放射学杂志, 2016,50(9):718-720. DOI:
10.3760/cma.j.issn.1005-1201.2016.09.021
.
[15]
Essig M , Tartaro A , Tartaglione T ,et al. Enhancing lesions of the brain: intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators[J]. Acad Radiol, 2006,13(6):744-751. DOI:
10.1016/j.acra.2006.02.056
.
[16]
Colosimo C , Demaerel P , Tortori-Donati P ,et al. Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumours in children[J]. Pediatr Radiol, 2005,35(5):501-510. DOI:
10.1007/s00247-004-1392-4
.
[17]
Colosimo C , Ruscalleda J , Korves M ,et al. Detection of intracranial metastases: a multicenter, intrapatient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dosage[J]. Invest Radiol, 2001,36(2):72-81.
[18]
Knopp MV , Runge VM , Essig M ,et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine[J]. Radiology, 2004,230(1):55-64. DOI:
10.1148/radiol.2301021085
.
[19]
王庆军,王勇,徐贤,等. 钆贝葡胺和钆喷酸葡胺在磁共振增强扫描诊断单发脑转移瘤中的对照研究[J]. 南方医科大学学报, 2011,31(12):1968-1973. DOI:
44-1627/R.20111207.1017.002
.
[20]
Colosimo C , Knopp MV , Barreau X ,et al. A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours[J]. Neuroradiology, 2004,46(8):655-665. DOI:
10.1007/s00234-003-1128-4
.
[21]
Rowley HA , Scialfa G , Gao PY ,et al. Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide[J]. AJNR Am J Neuroradiol, 2008,29(9):1684-1691. DOI:
10.3174/ajnr.A1185
.
[22]
Huang B , Liang CH , Liu HJ ,et al. Low-dose contrast-enhanced magnetic resonance imaging of brain metastases at 3.0 T using high-relaxivity contrast agents[J]. Acta Radiol, 2010,51(1):78-84. DOI:
10.3109/02841850903350178
.
[23]
刘红军,梁长虹,黄飚,等. 两种不同弛豫率钆对比剂在脑转移瘤中的磁共振对比研究[J]. 中国医学影像技术杂志, 2008,24(6):862-865. DOI:
10.3321/j.issn:1003-3289.2008.06.017
.
[24]
Maravilla KR , Maldjian JA , Schmalfuss IM ,et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents[J]. Radiology, 2006,240(2):389-400. DOI:
10.1148/radiol.2402051266
.
[25]
Rumboldt Z , Rowley HA , Steinberg F ,et al. Multicenter, double-blind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 tesla[J]. J Magn Reson Imaging, 2009,29(4):760-767. DOI:
10.1002/jmri.21695
.
[26]
Seidl Z , Vymazal J , Mechl M ,et al. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study)[J]. AJNR Am J Neuroradiol, 2012,33(6):1050-1058. DOI:
10.3174/ajnr.A3033
.
[27]
Khouri Chalouhi K , Papini GDE , Bandirali M ,et al. Less is better? Intraindividual and interindividual comparison between 0.075 mmol/kg of gadobenate dimeglumine and 0.1 mmol/kg of gadoterate meglumine for cranial MRI[J]. Eur J Radiol, 2014,83(7):1245-1249. DOI:
10.1016/j.ejrad.2014.03.030
.
[28]
Vaneckova M , Herman M , Smith MP ,et al. The benefits of high relaxivity for brain tumor imaging: results of a multicenter intraindividual crossover comparison of gadobenate dimeglumine with gadoterate meglumine (The BENEFIT Study)[J]. AJNR Am J Neuroradiol, 2015,36(9):1589-1598. DOI:
10.3174/ajnr.A4468
.
[29]
Erickson BJ , Campeau NG , Schreiner SA ,et al. Triple-dose contrast/magnetization transfer suppressed imaging of non-enhancing brain gliomas[J]. J Neurooncol, 2002,60(1):25-29.
[30]
ESUR. Guidelines Version 10.3; 2018[EB/OL]. http://www.esur.org/guidelines/. (accessed November 20, 2018).
[31]
Kanda T , Ishii K , Kawaguchi H ,et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material[J]. Radiology, 2014,270(3):834-841. DOI:
10.1148/radiol.13131669
.
[32]
Roberts DR , Chatterjee AR , Yazdani M ,et al. Pediatric patients demonstrate progressive T1-weighted hyperintensity in the dentate nucleus following multiple doses of gadolinium-based contrast agent[J]. AJNR Am J Neuroradiol, 2016,37(12):2340-2347. DOI:
10.3174/ajnr.A4891
.
[33]
Catalano C , Pediconi F , Nardis P ,et al. MR angiography with MultiHance for imaging the supra-aortic vessels[J]. Eur Radiol, 2004,14Suppl 7:O45-51.
[34]
Pediconi F , Fraioli F , Catalano C ,et al. Gadobenate dimeglumine (Gd-DTPA) vs gadopentetate dimeglumine (Gd-BOPTA) for contrast-enhanced magnetic resonance angiography (MRA): improvement in intravascular signal intensity and contrast to noise ratio[J]. Radiol Med, 2003,106(1-2):87-93.
[35]
Bueltmann E , Erb G , Kirchin MA ,et al. Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced magnetic resonance angiography of the supraaortic vessels at 3 Tesla[J]. Invest Radiol, 2008,43(10):695-702. DOI:
10.1097/RLI.0b013e31817d1505
.
[36]
Spampinato MV , Nguyen SA , Rumboldt Z . Comparison of gadobenate dimeglumine and gadodiamide in the evaluation of spinal vascular anatomy with MR angiography[J]. AJNR Am J Neuroradiol, 2010,31(6):1151-1156. DOI:
10.3174/ajnr.A1974
.
[37]
Prokop M , Schneider G , Vanzulli A ,et al. Contrast-enhanced MR Angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine[J]. Radiology, 2005,234(2):399-408. DOI:
10.1148/radiol.2342040023
.
[38]
Wyttenbach R , Gianella S , Alerci M ,et al. Prospective blinded evaluation of Gd-DOTA-versus Gd-BOPTA-enhanced peripheral MR angiography, as compared with digital subtraction angiography[J]. Radiology, 2003,227(1):261-269. DOI:
10.1148/radiol.2271011989
.
[39]
Pomper MG , Port JD . New techniques in MR imaging of brain tumors[J]. Magn Reson Imaging Clin N Am, 2000,8(4):691-713.
[40]
Essig M , Lodemann KP , Le-Huu M ,et al. Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T[J]. Invest Radiol, 2006,41(3):256-263. DOI:
10.1097/01.rli.0000191333.19068.6b
.
[41]
Morisetti A , Bussi S , Tirone P ,et al. Toxicological safety evaluation of gadobenate dimeglumine 0.5 M solution for injection (MultiHance), a new magnetic resonance imaging contrast medium[J]. J Comput Assist Tomogr, 1999,23Suppl 1:S207-S217.
[42]
Kuwatsuru R , Kadoya M , Ohtomo K ,et al. Clinical late phase II trials of MultiHance (Gd-BOPTA) for the magnetic resonance imaging of liver tumors in Japan[J]. J Comput Assist Tomogr, 1999,23Suppl 1:S65-S74.
[43]
Grazioli L , Morana G , Kirchin MA ,et al. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study[J]. Radiology, 2005,236(1):166-177. DOI:
10.1148/radiol.2361040338
.
[44]
Grazioli L , Morana G , Federle MP ,et al. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine[J]. Radiology, 2001,221(3):731-739. DOI:
10.1148/radiol.2213010139
.
[45]
Dillman JR , Ellis JH , Cohan RH ,et al. Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v. contrast media in children and adults[J]. AJR Am J Roentgenol, 2007,189(6):1533-1538. DOI:
10.2214/AJR.07.2554
.
[46]
Soares BP , Lequin MH , Huisman TAGM . Safety of contrast material use in children[J]. Magn Reson Imaging Clin N Am, 2017,25(4):779-785. DOI:
10.1016/j.mric.2017.06.009
.
[47]
Schneider G , Schürholz H , Kirchin MA ,et al. Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children[J]. Pediatr Radiol, 2013,43(2):202-211. DOI:
10.1007/s00247-012-2498-8
.
[48]
Heverhagen JT , Krombach GA , Gizewski E . Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis[J]. Rofo, 2014,186(7):661-669. DOI:
10.1055/s-0033-1356403
.
[49]
Nandwana SB , Moreno CC , Osipow MT ,et al. Gadobenate dimeglumine administration and nephrogenic systemic fibrosis: is there a real risk in patients with impaired renal function[J]. Radiology, 2015,276(3):741-747. DOI:
10.1148/radiol.2015142423
.
[50]
Bruce R , Wentland AL , Haemel AK ,et al. Incidence of nephrogenic systemic fibrosis using gadobenate dimeglumine in 1423 patients with renal insufficiency compared with gadodiamide[J]. Invest Radiol, 2016,51(11):701-705. DOI:
10.1097/RLI.0000000000000259
.
[51]
Soulez G , Bloomgarden DC , Rofsky NM ,et al. Prospective cohort study of nephrogenic systemic fibrosis in patients with stage 3-5 chronic kidney disease undergoing MRI with injected gadobenate dimeglumine or gadoteridol[J]. AJR Am J Roentgenol, 2015,205(3):469-478. DOI:
10.2214/AJR.14.14268
.
[52]
Kirchin MA , Lorusso V , Pirovano G . Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(®)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis[J]. Br J Radiol, 2015,88(1048):20140526. DOI:
10.1259/bjr.20140526
.
[53]
Zhang Y , Cao Y , Shih GL ,et al. Extent of signal hyperintensity on unenhanced T1-weighted brain MR images after more than 35 administrations of linear gadolinium-based contrast agents[J]. Radiology, 2017,282(2):516-525. DOI:
10.1148/radiol.2016152864
.
[54]
Kuno H , Jara H , Buch K ,et al. Global and regional brain assessment with quantitative MR imaging in patients with prior exposure to linear gadolinium-based contrast agents[J]. Radiology, 2017,283(1):195-204. DOI:
10.1148/radiol.2016160674
.
[55]
Bhargava R , Persad ARL , Bhargava NK ,et al. Multiple Administrations of gadobutrol in the pediatric brain: no change in T1 signal at MRI[J]. Radiology, 2018,289(1):204-209. DOI:
10.1148/radiol.2018172988
.
[56]
刘哲,杨健. 关注脑钆沉积问题,提高MR钆对比剂的安全应用水平[J]. 中华放射学杂志, 2018,52(12):889-891. DOI:
10.3760/cma.j.issn.1005-1201.2018.12.001
.
[57]
Schneider GK , Stroeder J , Roditi G ,et al. T1 signal measurements in pediatric brain: findings after multiple exposures to gadobenate dimeglumine for imaging of nonneurologic disease[J]. AJNR Am J Neuroradiol, 2017,38(9):1799-1806. DOI:
10.3174/ajnr.A5270
.
[58]
McDonald RJ , McDonald JS , Kallmes DF ,et al. Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without intracranial abnormalities[J]. Radiology, 2017,285(2):546-554. DOI:
10.1148/radiol.2017161595
.
[59]
FDA. FDA Drug Safety Communication: FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue[EB/OL]. https://www.fda.gov/Drugs/DrugSafety/ucm559007.htm. (accessed November 20, 2018).
[60]
FDA. FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings[EB/OL]. https://www.fda.gov/Drugs/DrugSafety/ucm589213.htm. (accessed November 20, 2018).
[61]
国家药品不良反应监测中心. 关注含钆对比剂反复使用引起脑部钆沉积风险[EB/OL]. http://www.cdr-adr.org.cn/xxtb_255/ypblfyxxtb/201712/t20171207_19826.html.
备注信息
A
李欣，天津市儿童医院影像科，300134，Email：
mocdef.3ab61jt.ilnix
B
彭芸，国家儿童医学中心 首都医科大学附属北京儿童医院影像科，100045，Email：
mocdef.oabohaynuygnepp
C
执笔者：陶晓娟，国家儿童医学中心首都医科大学附属北京儿童医院影像科，100045，Email：taotaoxiaojuan@sina.com；陈静，天津市儿童医院影像科，300134，Email：bbchenjing@126.com
D
所有作者均声明不存在利益冲突
评论 （0条）
注册 登录
时间排序
- 时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
多模态MRI在眼底疾病所致中枢神经系统变化中的研究进展
季禹 等 磁共振成像 2024,15(07)
儿童头颅及脊柱MR检查中国专家共识
中华医学会放射学分会儿科学组 等 中华放射学杂志 2022,56(07)
钆贝葡胺多期增强MRI预测肝细胞癌细胞角蛋白19表达状态的研究
郑婉静 等 中华放射学杂志 2021,55(06)
胎儿MRI中国专家共识
中华医学会放射学分会儿科学组 等 中华放射学杂志 2020,54(12)
分享
详细信息
表
访问与引文
阅读权限
参考文献
访问与引用
访问数据
0
0
全部时间 最近30天 最近6个月 最近12个月
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照
文献快照
N/A
N/A
AI总结中
N/A
N/A
快照内容由人工智能生成，供您参考。
你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。
0/50
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
0/2000
信息反馈
中文(简体)
英文
翻译
机器翻译功能由科大讯飞提供技术支持
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
你好！ 今天我能为您提供什么帮助？
0/30
of
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
扩写 缩写 改写 翻译
0/2000
信息反馈
历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大
翻译
润色
扩写
缩写
复制
引用
